A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes

What Was Tested

Researchers studied Mazdutide and Glucagon in this randomized controlled trial publication.

The patients, investigators and study site personnel involved in treating and assessing patients in each cohort were masked to IBI362 and placebo allocation.

Primary outcomes were safety and tolerability of IBI362.

Who Took Part

The study group was 43 patients.

Forty-two patients received the study treatment and were included in the analysis, with eight receiving IBI362, four receiving placebo and two receiving dulaglutide in each cohort.

How the Study Was Run

In design terms this was a randomized, open-label and placebo-controlled study.

Because people in this Mazdutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Mazdutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Some patients received a placebo instead of Mazdutide, giving a reference point.

What Was Measured

The patients, investigators and study site personnel involved in treating and assessing patients in each cohort were masked to IBI362 and placebo allocation.

Primary outcomes were safety and tolerability of IBI362.

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Glucagon, Glucagon-Like Peptide 1, Glycated Hemoglobin, Hypoglycemic Agents and Peptides.

What This Means in Plain Language

The paper is a randomized, open-label and placebo-controlled study of Mazdutide and Glucagon in 43 patients.

The publication is from 2022 (Nature communications), a journal based in England.

More context: the Mazdutide compound page and the Glucagon compound page, all human trials.